Pharmaceutical

Scorpius Holdings Commends the U.S. House of Representatives’ Passage of the BIOSECURE Act

Scorpius Poised to Support Expanded U.S. Government-Backed Project Pipeline as U.S. Drugmakers Seek to Shift to Domestic Suppliers Amid Industry-Changing…

4 months ago

Biogen Board Appoints Two New Independent Directors

Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and developmentCAMBRIDGE,…

4 months ago

Enable Injections Announces Agreement with Sobi® to Develop and Distribute Aspaveli® in Combination with enFuse® in Sobi Territories

CINCINNATI, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug…

4 months ago

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

SAN MATEO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing…

4 months ago

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

Centers for Disease Control and Prevention (CDC) reports death rate due to COVID-19 has continued to increase throughout 2024 Immunocompromised…

4 months ago

Lifecore Biomedical Regains Compliance with Nasdaq Listing Requirements

CHASKA, Minn., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated…

4 months ago

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well…

4 months ago

F2G Announces $100 Million Financing to Advance Late-Stage Development and Commercialization of Novel Antifungal Drug Candidate Olorofim in the US

Financing is being led by new investor AMR Action Fund with strong participation from new investor ICG Life Sciences and…

4 months ago

Harvey Homan to Highlight MetasTx’s Game-Changing Approach to Cancer Treatment at PA Life Science Futures

PITTSBURGH, Sept. 12, 2024 (GLOBE NEWSWIRE) -- MetasTx LLC, a biopharmaceutical company dedicated to developing innovative therapies for cancer metastasis,…

4 months ago

Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

― Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo…

4 months ago